EyeGate Pharma begins phase 3 study on potential treatment for anterior uveitis
OSN SuperSite
EGP-437 administered with the EyeGate II Drug Delivery System will have its effectiveness measured against topically applied prednisolone acetate eye drops. "Based on the positive clinical results from the phase 2 study, we are excited to initiate this ...
EyeGate begins patient enrollment in anterior uveitis studyPharmaceutical Business Review

all 2 news articles »